In vivo, this comprehensive reprogramming of PD-L1 and exosomal PD-L1 alleviated systemic immunosuppression, enhanced CD8+ T cell infiltration and activation, and significantly inhibited tumor growth. This evidence concerns the gene CD8A and neoplasm.